Loss of anti-hepatitis C virus antibodies following therapeutic sustained virological response in a HIV co-infected patient

Sarah Maylin; Nathalie Colin de Verdière; Maud Salmona; François Simon; Constance Delaugerre

doi:10.1016/j.jiac.2014.01.006

Loss of anti-hepatitis C virus antibodies following therapeutic sustained virological response in a HIV co-infected patient

J Infect Chemother. 2014 Jun;20(6):384-6. doi: 10.1016/j.jiac.2014.01.006. Epub 2014 Mar 6.

Authors

Sarah Maylin¹, Nathalie Colin de Verdière², Maud Salmona³, François Simon³, Constance Delaugerre³

Affiliations

¹ Service de Microbiologie, University Paris Diderot, Hôpital Saint Louis, Paris, 75010 Paris, France. Electronic address: sarah.maylin@sls.aphp.fr.
² Service de Maladies Infectieuses, University Paris Diderot, Hôpital Saint Louis, 75010 Paris, France.
³ Service de Microbiologie, University Paris Diderot, Hôpital Saint Louis, Paris, 75010 Paris, France.

PMID: 24613600
DOI: 10.1016/j.jiac.2014.01.006

Abstract

No data are available for the kinetics of anti-Hepatitis C Virus (HCV) antibodies in HIV/HCV co-infected patients after sustained virological response (SVR). We present a case of a HIV/HCV co-infected patient, showing a significant anti-HCV antibodies decrease during therapy, who achieved a HCV seroreversion 3 years after SVR. Among them, antibodies to core protein, the most strongly antigenic protein showed significant decrease. Our results indicate an absence of antigenic stimulation suggesting a total clearance of HCV.

Keywords: Clearance; HCV; HIV; SVR; anti-HCV antibodies.

Publication types

Case Reports

MeSH terms

Adult
Antiviral Agents / therapeutic use
HIV Infections / drug therapy
HIV Infections / immunology
HIV Infections / virology*
Hepatitis C / drug therapy
Hepatitis C / immunology*
Hepatitis C / virology*
Hepatitis C Antibodies / blood*
Humans
Male
Treatment Outcome
Viral Load

Substances

Antiviral Agents
Hepatitis C Antibodies